<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730158</url>
  </required_header>
  <id_info>
    <org_study_id>12-005</org_study_id>
    <secondary_id>ACS IRG 58-012-49</secondary_id>
    <nct_id>NCT00730158</nct_id>
  </id_info>
  <brief_title>A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Chu, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kadmon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as
      an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our
      rationale for the therapeutic use of KD018 is its potential activity in reducing
      chemotherapy-induced toxicity, especially diarrhea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KD018 is an oral form of a spray dried aqueous extract composed of four main herbs, which
      have been used in the Orient for nearly 2000 years for a variety of GI symptoms including
      diarrhea and nausea/vomiting. Extensive pre-clinical research has been done with Chinese
      herbal medicine, and studies have documented significant anticancer activity in combination
      with various cytotoxic agents including Irinotecan, which is a semi-synthetic derivative of
      the natural alkaloid camptothecin and belongs to the class of topoisomerase I inhibitors.
      Irinotecan has been evaluated extensively as a single agent as well as in combination with
      other cytotoxic agents in several schedules. We recently completed a phase I study of
      irinotecan using the every-2-week schedule in combination with varying doses of KD018. Based
      on this phase I study, the dose of irinotecan that will be used in this study is 215 mg/m2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Grade 2-4 Toxicities</measure>
    <time_frame>Up to 3 months after start of study treatment</time_frame>
    <description>The proportion of participants with a toxicity grade greater than or equal to grade 2, per NCI CTCAE 4.0. Toxicity is defined as any adverse event (AE) at least probably related to treatment occurring with 90 days of the beginning of treatment. The worst grade of AE at least probably related to treatment was determined for each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of participants who experienced a best response of Partial Response (PR) or Stable Disease (SD) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), PR is &gt;=30% decrease in the sum of the longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 450 days</time_frame>
    <description>Median number of days and after the treatment participants remained alive without worsening disease.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 900 days</time_frame>
    <description>Median number of days from the start of treatment that study participants remained alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response (CR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of patients that experienced Progressed Disease, Stable Disease or Partial Response per RECIST 1.1. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters, and Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy (Diarrhea) FACIT-D Total Score</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. The Functional Assessment of Chronic Illness Therapy (Diarrhea), the FACIT-D, contains 11 items which address concerns related to treatment-related diarrhea. Responses are on a Likert scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. Thus, total scores can range from 0 to 44. Higher scores relate to better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-D - PWB: Physical Well-Being</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy FACIT-D - PWB: Physical Well-Being is a 7-item subscale score of the total FACIT-D self-assessment that measures a patient's physical well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better physical well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-D EWB: Emotional Well-Being</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Emotional Well-Being (EWB) is a 6-item subscale score of the total FACIT-D self-assessment that measures a patient's emotional well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-24. Higher scores related to better emotional well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-D SWB: Social Well-Being</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Social Well-Being (SWB) is a 7-item subset score of the total FACIT-D self-assessment that measures a patient's social well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better social well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-D FWB: Functional Well-Being</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Functional Well-Being (FWB) is a 7-item subscale of the FACIT-D that measures a patient's functional well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better family well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-D FACTG: FACT-G Total Score (PWB+SWB+EWB+FWB)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The FACIT-D FACTG: FACT-G Total Score is a total of PWB (Physical Well-Being)+SWB (Social Well-Being)+EWB (Emotional Well-Being)+FWB (Functional Well-Being) subset scores. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-108. Higher scores indicate greater well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-Fatigue FS: Fatigue Score</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy FACIT-Fatigue FS: Fatigue Score is a 13 -item self-reporting assessment that measures fatigue related to their illness. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-52. Higher scores indicate better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Chronic Illness Therapy FACIT-D TOI: Trial Outcome Index</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy FACIT-D TOI: Trial Outcome Index. is the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and &quot;additional concerns&quot; subscales of the FACIT-D. The TOI is an efficient summary index of physical/functional outcomes. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score can range from 0-100. Higher scores relate to better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites and Cytokine Scoring for Prediction of Time to Disease Progression</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of patients with metabolites in their blood samples with a score less than 4.8 and greater than 4.8. A Cox Proportional Hazard Regression Analysis was fitted using survival time, status to the cytokines and metabolites as covariates. The analysis computes beta coefficients (hazard ratios) for each cytokine/metabolite. Scores higher than a threshold value of 4.8 were associated with higher overall survival than patients who scored less than 4.8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 Alleles</measure>
    <time_frame>From 30 minutes prior to irinotecan infusion through to Immediately after irinotecan infusion, up to 8 weeks</time_frame>
    <description>The number of patients with specific polymorphisms of UGT1A1 using genotype analysis of peripheral blood sample. UGT1A1*1 is the wild-type allele associated with normal enzyme activity. Patients with genotypic status of 7/7 are at an increased risk of neutropenia following intravenous irinotecan therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor DNA - Percentage of Patients With DNA Mutations</measure>
    <time_frame>Baseline - prior to treatment</time_frame>
    <description>Percentage of patients with Braf, Kras, Nras, PIK3CA and PTEN mutations associated with tumor detected in the circulating DNA of plasma, before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor DNA - Percentage of Patients With DNA Mutations</measure>
    <time_frame>End of treatment - up to 8 weeks</time_frame>
    <description>Percentage of patients with Braf, Kras, Nras, PIK3CA and PTEN mutations associated with tumor detected in the circulating DNA of plasma, before treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan+ KD018</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD018</intervention_name>
    <description>Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed metastatic colorectal cancer (mCRC), who have
             received and/or progressed on a prior oxaliplatin-based chemotherapy regimen.

          2. Patients must have been off of chemotherapy for at least 4 weeks prior to signing the
             informed consent/start of screening.

          3. Patients with wild-type or mutant KRAS mCRC.

          4. At least one measurable lesion by RECIST 1.1.

          5. ECOG PS Performance Status 0-2.

          6. Must be &gt;/=18 years of age.

          7. Expected survival of at least 6 months.

          8. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must use acceptable contraceptive methods (abstinence, intrauterine device
             [IUD], oral contraceptive or double barrier device), and must have a negative serum or
             urine pregnancy test within 1 week prior to beginning treatment on this trial. Nursing
             patients are excluded. Sexually active men must also use acceptable contraceptive
             methods. Pregnant and nursing patients are excluded because the effects of the
             combination of KD018 and irinotecan on a fetus or nursing child are unknown.

          9. Must be able and willing to give written informed consent.

         10. Patients must have the following clinical laboratory values:

               1. ANC count &gt;/= 1,500/ mm3.

               2. Platelets &gt;/= 100,000/ mm3.

               3. Hemoglobin &gt;/= 9 gm/dL (may be corrected by transfusion).

         11. Evidence of adequate hepatic function, Bilirubin &lt; 1.5 x upper limit of normal (ULN)
             AST &lt;/= 2.5 x ULN or ALT &lt;/= 2.5 x ULN (Note, if both AST and ALT are done, both must
             be &lt;/= 2.5 x ULN) OR AST &lt;/= 5.0 x ULN or ALT &lt;/= 5.0 x ULN is acceptable if liver has
             tumor involvement. (Note, if both AST and ALT are done, both must be &lt;/= 5.0 x ULN)

         12. Serum creatinine &lt;/=2 x ULN

         13. Serum potassium within institutional limits of normal (may be corrected with potassium
             repletion).

        Exclusion Criteria:

          1. Continued treatment with bevacizumab with documented evidence of disease progression
             on a bevacizumab-containing regimen.

          2. Uncontrolled or symptomatic brain metastasis.

          3. Serious concomitant systemic disorders (e.g., active infection) that, in the opinion
             of the investigator, would compromise the safety of the patient or compromise the
             patient's ability to complete the study.

          4. Unwilling or unable to follow protocol requirements or to give informed consent.

          5. No treatment with cytotoxic or biologic agents within the 4 weeks prior to beginning
             treatment on this study (6 weeks for mitomycin or nitrosoureas). At least 4 weeks must
             have elapsed from any prior surgery, radiation, hormonal or other drug therapy for
             their cancer.

          6. Known HIV positivity, as safety in this patient population has not been assessed.

          7. Presence of metastatic disease that, in the opinion of the investigator, would require
             palliative treatment within 4 weeks of enrollment.

          8. Altered mental status precluding understanding of the informed consent process and/or
             completion of the necessary studies.

          9. Pregnant or breast-feeding women.

         10. Men and women of childbearing age and potential, who are not willing to use effective
             contraception.

         11. Major surgery within the previous 4 weeks.

         12. Patients taking concurrent medications of any kind which are strong inducers or
             inhibitors of CYP3A4.

         13. Patients previously treated with an irinotecan-containing regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Chu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hillman Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman CancerCenters</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>August 15, 2018</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2019</results_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Edward Chu, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Irinotecan+ KD018</title>
          <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
        </group>
        <group group_id="P2">
          <title>Irinotecan + Placebo</title>
          <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Irinotecan+ KD018</title>
          <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
        </group>
        <group group_id="B2">
          <title>Irinotecan + Placebo</title>
          <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="12.4"/>
                    <measurement group_id="B2" value="57.6" spread="12.7"/>
                    <measurement group_id="B3" value="61.7" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With Grade 2-4 Toxicities</title>
        <description>The proportion of participants with a toxicity grade greater than or equal to grade 2, per NCI CTCAE 4.0. Toxicity is defined as any adverse event (AE) at least probably related to treatment occurring with 90 days of the beginning of treatment. The worst grade of AE at least probably related to treatment was determined for each participant.</description>
        <time_frame>Up to 3 months after start of study treatment</time_frame>
        <population>Participants that received at least 3 months of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Grade 2-4 Toxicities</title>
          <description>The proportion of participants with a toxicity grade greater than or equal to grade 2, per NCI CTCAE 4.0. Toxicity is defined as any adverse event (AE) at least probably related to treatment occurring with 90 days of the beginning of treatment. The worst grade of AE at least probably related to treatment was determined for each participant.</description>
          <population>Participants that received at least 3 months of study treatment.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.35" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.40" lower_limit="0.16" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response (OR)</title>
        <description>Number of participants who experienced a best response of Partial Response (PR) or Stable Disease (SD) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), PR is &gt;=30% decrease in the sum of the longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameter.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Participants evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m²..
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response (OR)</title>
          <description>Number of participants who experienced a best response of Partial Response (PR) or Stable Disease (SD) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), PR is &gt;=30% decrease in the sum of the longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameter.</description>
          <population>Participants evaluable for response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Median number of days and after the treatment participants remained alive without worsening disease.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
        <time_frame>Up to 450 days</time_frame>
        <population>Patients that were evaluable for response and survival data were obtainable.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Median number of days and after the treatment participants remained alive without worsening disease.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
          <population>Patients that were evaluable for response and survival data were obtainable.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="106" upper_limit="NA">Statistically Not Reached.</measurement>
                    <measurement group_id="O2" value="104" lower_limit="52" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Median number of days from the start of treatment that study participants remained alive.</description>
        <time_frame>Up to 900 days</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Median number of days from the start of treatment that study participants remained alive.</description>
          <population>All participants.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291" lower_limit="174" upper_limit="NA">Statistically Not Reached</measurement>
                    <measurement group_id="O2" value="482" lower_limit="308" upper_limit="NA">Statistically Not Reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response (CR)</title>
        <description>Number of patients that experienced Progressed Disease, Stable Disease or Partial Response per RECIST 1.1. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters, and Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Participants that were evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response (CR)</title>
          <description>Number of patients that experienced Progressed Disease, Stable Disease or Partial Response per RECIST 1.1. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters, and Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
          <population>Participants that were evaluable for response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progressed Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy (Diarrhea) FACIT-D Total Score</title>
        <description>The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. The Functional Assessment of Chronic Illness Therapy (Diarrhea), the FACIT-D, contains 11 items which address concerns related to treatment-related diarrhea. Responses are on a Likert scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. Thus, total scores can range from 0 to 44. Higher scores relate to better functioning.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACIT-D during any single treatment cycle (every 2 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy (Diarrhea) FACIT-D Total Score</title>
          <description>The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. The Functional Assessment of Chronic Illness Therapy (Diarrhea), the FACIT-D, contains 11 items which address concerns related to treatment-related diarrhea. Responses are on a Likert scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. Thus, total scores can range from 0 to 44. Higher scores relate to better functioning.</description>
          <population>Maximum number of participants that completed the FACIT-D during any single treatment cycle (every 2 weeks).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.09" lower_limit="36.02" upper_limit="44.16"/>
                    <measurement group_id="O2" value="39.77" lower_limit="36.98" upper_limit="42.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.66" lower_limit="34.37" upper_limit="40.95"/>
                    <measurement group_id="O2" value="35.55" lower_limit="30.98" upper_limit="40.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.78" lower_limit="28.57" upper_limit="40.98"/>
                    <measurement group_id="O2" value="37.78" lower_limit="33.09" upper_limit="42.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.75" lower_limit="32.64" upper_limit="42.86"/>
                    <measurement group_id="O2" value="35.65" lower_limit="29.48" upper_limit="41.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.62" lower_limit="30.10" upper_limit="41.15"/>
                    <measurement group_id="O2" value="35.71" lower_limit="29.89" upper_limit="41.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.09" lower_limit="29.93" upper_limit="44.24"/>
                    <measurement group_id="O2" value="31.25" lower_limit="25.53" upper_limit="36.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.54" lower_limit="29.52" upper_limit="43.57"/>
                    <measurement group_id="O2" value="30.38" lower_limit="19.30" upper_limit="41.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.60" lower_limit="31.49" upper_limit="45.71"/>
                    <measurement group_id="O2" value="29.33" lower_limit="19.06" upper_limit="39.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.50" lower_limit="23.10" upper_limit="53.90"/>
                    <measurement group_id="O2" value="28.20" lower_limit="18.14" upper_limit="38.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.67" lower_limit="16.69" upper_limit="54.64"/>
                    <measurement group_id="O2" value="32.50" lower_limit="0.73" upper_limit="64.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" lower_limit="4.59" upper_limit="55.41"/>
                    <measurement group_id="O2" value="31.50" lower_limit="-25.68" upper_limit="88.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-D - PWB: Physical Well-Being</title>
        <description>The Functional Assessment of Chronic Illness Therapy FACIT-D - PWB: Physical Well-Being is a 7-item subscale score of the total FACIT-D self-assessment that measures a patient's physical well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better physical well-being.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-D - PWB: Physical Well-Being</title>
          <description>The Functional Assessment of Chronic Illness Therapy FACIT-D - PWB: Physical Well-Being is a 7-item subscale score of the total FACIT-D self-assessment that measures a patient's physical well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better physical well-being.</description>
          <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.18" lower_limit="21.09" upper_limit="25.27"/>
                    <measurement group_id="O2" value="21.79" lower_limit="18.14" upper_limit="25.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.69" lower_limit="17.70" upper_limit="25.68"/>
                    <measurement group_id="O2" value="22.00" lower_limit="18.64" upper_limit="25.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.00" lower_limit="18.27" upper_limit="25.73"/>
                    <measurement group_id="O2" value="22.21" lower_limit="18.64" upper_limit="25.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.26" lower_limit="22.40" upper_limit="26.12"/>
                    <measurement group_id="O2" value="21.30" lower_limit="17.18" upper_limit="25.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.67" lower_limit="20.12" upper_limit="25.22"/>
                    <measurement group_id="O2" value="23.09" lower_limit="20.62" upper_limit="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.62" lower_limit="20.95" upper_limit="26.30"/>
                    <measurement group_id="O2" value="21.88" lower_limit="17.08" upper_limit="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.50" lower_limit="21.09" upper_limit="25.91"/>
                    <measurement group_id="O2" value="20.00" lower_limit="14.37" upper_limit="25.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.14" lower_limit="19.67" upper_limit="24.61"/>
                    <measurement group_id="O2" value="20.83" lower_limit="16.31" upper_limit="25.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.67" lower_limit="19.37" upper_limit="25.96"/>
                    <measurement group_id="O2" value="17.40" lower_limit="11.81" upper_limit="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.00" lower_limit="15.64" upper_limit="28.36"/>
                    <measurement group_id="O2" value="22.50" lower_limit="-9.27" upper_limit="54.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.33" lower_limit="10.83" upper_limit="35.84"/>
                    <measurement group_id="O2" value="23.50" lower_limit="17.15" upper_limit="29.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-D EWB: Emotional Well-Being</title>
        <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Emotional Well-Being (EWB) is a 6-item subscale score of the total FACIT-D self-assessment that measures a patient's emotional well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-24. Higher scores related to better emotional well-being.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle (every 2 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-D EWB: Emotional Well-Being</title>
          <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Emotional Well-Being (EWB) is a 6-item subscale score of the total FACIT-D self-assessment that measures a patient's emotional well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-24. Higher scores related to better emotional well-being.</description>
          <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle (every 2 weeks).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.85" lower_limit="17.87" upper_limit="21.82"/>
                    <measurement group_id="O2" value="16.43" lower_limit="13.48" upper_limit="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" lower_limit="15.19" upper_limit="20.81"/>
                    <measurement group_id="O2" value="16.43" lower_limit="13.33" upper_limit="19.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.96" lower_limit="17.36" upper_limit="22.55"/>
                    <measurement group_id="O2" value="17.30" lower_limit="14.06" upper_limit="20.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.11" lower_limit="17.52" upper_limit="22.70"/>
                    <measurement group_id="O2" value="17.76" lower_limit="14.11" upper_limit="21.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" lower_limit="16.76" upper_limit="21.91"/>
                    <measurement group_id="O2" value="19.55" lower_limit="17.39" upper_limit="21.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.38" lower_limit="17.81" upper_limit="22.94"/>
                    <measurement group_id="O2" value="18.75" lower_limit="15.22" upper_limit="22.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.88" lower_limit="17.53" upper_limit="22.22"/>
                    <measurement group_id="O2" value="17.20" lower_limit="11.35" upper_limit="23.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.57" lower_limit="18.25" upper_limit="22.89"/>
                    <measurement group_id="O2" value="17.80" lower_limit="12.95" upper_limit="22.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.33" lower_limit="17.88" upper_limit="22.79"/>
                    <measurement group_id="O2" value="15.50" lower_limit="6.00" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.25" lower_limit="16.87" upper_limit="25.63"/>
                    <measurement group_id="O2" value="21.00" lower_limit="-4.41" upper_limit="46.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.00" lower_limit="17.03" upper_limit="26.97"/>
                    <measurement group_id="O2" value="20.30" lower_limit="3.78" upper_limit="36.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-D SWB: Social Well-Being</title>
        <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Social Well-Being (SWB) is a 7-item subset score of the total FACIT-D self-assessment that measures a patient's social well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better social well-being.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-D SWB: Social Well-Being</title>
          <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Social Well-Being (SWB) is a 7-item subset score of the total FACIT-D self-assessment that measures a patient's social well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better social well-being.</description>
          <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.85" lower_limit="24.74" upper_limit="26.96"/>
                    <measurement group_id="O2" value="23.91" lower_limit="20.52" upper_limit="27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.46" lower_limit="17.01" upper_limit="25.92"/>
                    <measurement group_id="O2" value="24.33" lower_limit="21.30" upper_limit="27.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.74" lower_limit="14.07" upper_limit="27.41"/>
                    <measurement group_id="O2" value="25.60" lower_limit="23.70" upper_limit="27.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.09" lower_limit="22.16" upper_limit="28.03"/>
                    <measurement group_id="O2" value="25.33" lower_limit="23.74" upper_limit="26.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.43" lower_limit="20.17" upper_limit="26.68"/>
                    <measurement group_id="O2" value="24.60" lower_limit="21.23" upper_limit="27.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.07" lower_limit="21.71" upper_limit="28.44"/>
                    <measurement group_id="O2" value="24.29" lower_limit="19.09" upper_limit="29.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.19" lower_limit="15.33" upper_limit="29.04"/>
                    <measurement group_id="O2" value="23.60" lower_limit="21.90" upper_limit="24.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.83" lower_limit="21.76" upper_limit="29.91"/>
                    <measurement group_id="O2" value="22.89" lower_limit="19.05" upper_limit="26.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.22" lower_limit="19.58" upper_limit="28.87"/>
                    <measurement group_id="O2" value="21.63" lower_limit="15.45" upper_limit="27.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" lower_limit="20.42" upper_limit="30.92"/>
                    <measurement group_id="O2" value="23.00" lower_limit="-2.41" upper_limit="48.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.94" lower_limit="14.21" upper_limit="35.68"/>
                    <measurement group_id="O2" value="23.50" lower_limit="-8.27" upper_limit="55.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-D FWB: Functional Well-Being</title>
        <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Functional Well-Being (FWB) is a 7-item subscale of the FACIT-D that measures a patient's functional well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better family well-being.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-D FWB: Functional Well-Being</title>
          <description>The Functional Assessment of Chronic Illness Therapy FACIT-D Functional Well-Being (FWB) is a 7-item subscale of the FACIT-D that measures a patient's functional well-being. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-28. Higher scores related to better family well-being.</description>
          <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.85" lower_limit="16.48" upper_limit="23.21"/>
                    <measurement group_id="O2" value="18.07" lower_limit="14.44" upper_limit="21.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.89" lower_limit="14.62" upper_limit="23.17"/>
                    <measurement group_id="O2" value="17.21" lower_limit="13.84" upper_limit="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.78" lower_limit="15.43" upper_limit="24.97"/>
                    <measurement group_id="O2" value="20.20" lower_limit="14.46" upper_limit="25.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.11" lower_limit="15.59" upper_limit="24.63"/>
                    <measurement group_id="O2" value="19.32" lower_limit="14.33" upper_limit="24.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.44" lower_limit="15.47" upper_limit="23.42"/>
                    <measurement group_id="O2" value="19.09" lower_limit="14.86" upper_limit="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.77" lower_limit="16.09" upper_limit="23.46"/>
                    <measurement group_id="O2" value="20.50" lower_limit="10.56" upper_limit="30.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.62" lower_limit="15.48" upper_limit="23.77"/>
                    <measurement group_id="O2" value="17.00" lower_limit="10.31" upper_limit="23.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.00" lower_limit="12.98" upper_limit="25.02"/>
                    <measurement group_id="O2" value="16.40" lower_limit="10.74" upper_limit="22.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.83" lower_limit="14.85" upper_limit="24.82"/>
                    <measurement group_id="O2" value="17.00" lower_limit="7.19" upper_limit="26.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.58" lower_limit="7.19" upper_limit="26.81"/>
                    <measurement group_id="O2" value="20.50" lower_limit="14.85" upper_limit="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.00" lower_limit="-35.68" upper_limit="78.68"/>
                    <measurement group_id="O2" value="21.50" lower_limit="2.25" upper_limit="39.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-D FACTG: FACT-G Total Score (PWB+SWB+EWB+FWB)</title>
        <description>The FACIT-D FACTG: FACT-G Total Score is a total of PWB (Physical Well-Being)+SWB (Social Well-Being)+EWB (Emotional Well-Being)+FWB (Functional Well-Being) subset scores. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-108. Higher scores indicate greater well-being.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACT-G during any single treatment cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan+ KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-D FACTG: FACT-G Total Score (PWB+SWB+EWB+FWB)</title>
          <description>The FACIT-D FACTG: FACT-G Total Score is a total of PWB (Physical Well-Being)+SWB (Social Well-Being)+EWB (Emotional Well-Being)+FWB (Functional Well-Being) subset scores. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-108. Higher scores indicate greater well-being.</description>
          <population>Maximum number of participants that completed the FACT-G during any single treatment cycle.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.72" lower_limit="82.18" upper_limit="95.26"/>
                    <measurement group_id="O2" value="80.19" lower_limit="68.66" upper_limit="91.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.05" lower_limit="68.46" upper_limit="91.64"/>
                    <measurement group_id="O2" value="79.98" lower_limit="69.37" upper_limit="90.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.47" lower_limit="69.52" upper_limit="95.42"/>
                    <measurement group_id="O2" value="84.99" lower_limit="72.48" upper_limit="97.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.57" lower_limit="79.78" upper_limit="99.37"/>
                    <measurement group_id="O2" value="83.70" lower_limit="70.54" upper_limit="96.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.87" lower_limit="75.61" upper_limit="94.13"/>
                    <measurement group_id="O2" value="86.33" lower_limit="76.32" upper_limit="96.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.85" lower_limit="78.33" upper_limit="99.36"/>
                    <measurement group_id="O2" value="85.42" lower_limit="64.40" upper_limit="106.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.19" lower_limit="73.99" upper_limit="96.38"/>
                    <measurement group_id="O2" value="79.07" lower_limit="65.44" upper_limit="92.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.55" lower_limit="75.96" upper_limit="99.13"/>
                    <measurement group_id="O2" value="76.43" lower_limit="60.23" upper_limit="92.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.06" lower_limit="74.44" upper_limit="99.67"/>
                    <measurement group_id="O2" value="74.79" lower_limit="48.58" upper_limit="101.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.50" lower_limit="73.24" upper_limit="109.76"/>
                    <measurement group_id="O2" value="87.00" lower_limit="-65.47" upper_limit="239.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.28" lower_limit="53.15" upper_limit="129.40"/>
                    <measurement group_id="O2" value="88.80" lower_limit="-23.01" upper_limit="200.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-Fatigue FS: Fatigue Score</title>
        <description>The Functional Assessment of Chronic Illness Therapy FACIT-Fatigue FS: Fatigue Score is a 13 -item self-reporting assessment that measures fatigue related to their illness. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-52. Higher scores indicate better functioning.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-Fatigue FS: Fatigue Score</title>
          <description>The Functional Assessment of Chronic Illness Therapy FACIT-Fatigue FS: Fatigue Score is a 13 -item self-reporting assessment that measures fatigue related to their illness. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score ranges from 0-52. Higher scores indicate better functioning.</description>
          <population>Maximum number of participants that completed the FACT-Fatigue FS during any single treatment cycle.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.39" lower_limit="36.50" upper_limit="46.28"/>
                    <measurement group_id="O2" value="36.17" lower_limit="28.42" upper_limit="43.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.09" lower_limit="26.22" upper_limit="45.96"/>
                    <measurement group_id="O2" value="36.67" lower_limit="30.36" upper_limit="42.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.80" lower_limit="32.68" upper_limit="44.92"/>
                    <measurement group_id="O2" value="38.45" lower_limit="30.44" upper_limit="46.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.67" lower_limit="36.57" upper_limit="46.77"/>
                    <measurement group_id="O2" value="36.22" lower_limit="27.19" upper_limit="45.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.22" lower_limit="36.18" upper_limit="44.27"/>
                    <measurement group_id="O2" value="38.56" lower_limit="30.64" upper_limit="46.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.25" lower_limit="36.02" upper_limit="44.48"/>
                    <measurement group_id="O2" value="39.75" lower_limit="23.77" upper_limit="55.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.53" lower_limit="36.03" upper_limit="47.03"/>
                    <measurement group_id="O2" value="30.72" lower_limit="20.11" upper_limit="41.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.33" lower_limit="34.67" upper_limit="47.99"/>
                    <measurement group_id="O2" value="33.33" lower_limit="22.74" upper_limit="43.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.78" lower_limit="28.92" upper_limit="52.65"/>
                    <measurement group_id="O2" value="30.20" lower_limit="14.96" upper_limit="45.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.25" lower_limit="29.59" upper_limit="50.91"/>
                    <measurement group_id="O2" value="33.33" lower_limit="-1.47" upper_limit="68.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.50" lower_limit="30.14" upper_limit="52.86"/>
                    <measurement group_id="O2" value="40.00" lower_limit="-36.24" upper_limit="116.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Functional Assessment of Chronic Illness Therapy FACIT-D TOI: Trial Outcome Index</title>
        <description>The Functional Assessment of Chronic Illness Therapy FACIT-D TOI: Trial Outcome Index. is the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and &quot;additional concerns&quot; subscales of the FACIT-D. The TOI is an efficient summary index of physical/functional outcomes. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score can range from 0-100. Higher scores relate to better functioning.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Maximum number of participants that completed the FACIT-D during any single treatment cycle (every 2 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan+ KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Functional Assessment of Chronic Illness Therapy FACIT-D TOI: Trial Outcome Index</title>
          <description>The Functional Assessment of Chronic Illness Therapy FACIT-D TOI: Trial Outcome Index. is the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and &quot;additional concerns&quot; subscales of the FACIT-D. The TOI is an efficient summary index of physical/functional outcomes. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness. Individual responses are scale and range from 0 = &quot;Not at all&quot; to 4 = &quot;Very Much&quot;. The total score can range from 0-100. Higher scores relate to better functioning.</description>
          <population>Maximum number of participants that completed the FACIT-D during any single treatment cycle (every 2 weeks).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.03" lower_limit="75.36" upper_limit="88.70"/>
                    <measurement group_id="O2" value="79.23" lower_limit="71.42" upper_limit="87.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.01" lower_limit="68.39" upper_limit="87.63"/>
                    <measurement group_id="O2" value="75.17" lower_limit="66.46" upper_limit="83.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.56" lower_limit="62.84" upper_limit="90.27"/>
                    <measurement group_id="O2" value="82.42" lower_limit="72.85" upper_limit="91.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.88" lower_limit="71.97" upper_limit="91.78"/>
                    <measurement group_id="O2" value="76.27" lower_limit="62.73" upper_limit="89.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.12" lower_limit="68.15" upper_limit="86.10"/>
                    <measurement group_id="O2" value="79.11" lower_limit="67.99" upper_limit="90.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.40" lower_limit="67.97" upper_limit="92.82"/>
                    <measurement group_id="O2" value="73.62" lower_limit="56.42" upper_limit="90.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.11" lower_limit="68.09" upper_limit="90.14"/>
                    <measurement group_id="O2" value="66.46" lower_limit="47.02" upper_limit="85.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.00" lower_limit="67.33" upper_limit="96.67"/>
                    <measurement group_id="O2" value="65.40" lower_limit="47.27" upper_limit="83.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.25" lower_limit="55.74" upper_limit="106.76"/>
                    <measurement group_id="O2" value="61.50" lower_limit="33.62" upper_limit="89.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.44" lower_limit="38.37" upper_limit="122.52"/>
                    <measurement group_id="O2" value="75.50" lower_limit="-57.92" upper_limit="208.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.50" lower_limit="-1.38" upper_limit="138.38"/>
                    <measurement group_id="O2" value="76.50" lower_limit="-44.21" upper_limit="197.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolites and Cytokine Scoring for Prediction of Time to Disease Progression</title>
        <description>Number of patients with metabolites in their blood samples with a score less than 4.8 and greater than 4.8. A Cox Proportional Hazard Regression Analysis was fitted using survival time, status to the cytokines and metabolites as covariates. The analysis computes beta coefficients (hazard ratios) for each cytokine/metabolite. Scores higher than a threshold value of 4.8 were associated with higher overall survival than patients who scored less than 4.8.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Patients that received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolites and Cytokine Scoring for Prediction of Time to Disease Progression</title>
          <description>Number of patients with metabolites in their blood samples with a score less than 4.8 and greater than 4.8. A Cox Proportional Hazard Regression Analysis was fitted using survival time, status to the cytokines and metabolites as covariates. The analysis computes beta coefficients (hazard ratios) for each cytokine/metabolite. Scores higher than a threshold value of 4.8 were associated with higher overall survival than patients who scored less than 4.8.</description>
          <population>Patients that received study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scores &lt; 4.8 (two metabolites)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores &gt; 4.8 (two metabolites)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores &lt; 4.8 (one metabolite+two cytokine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores &gt; 4.8 (one metabolite+two cytokine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 Alleles</title>
        <description>The number of patients with specific polymorphisms of UGT1A1 using genotype analysis of peripheral blood sample. UGT1A1*1 is the wild-type allele associated with normal enzyme activity. Patients with genotypic status of 7/7 are at an increased risk of neutropenia following intravenous irinotecan therapy.</description>
        <time_frame>From 30 minutes prior to irinotecan infusion through to Immediately after irinotecan infusion, up to 8 weeks</time_frame>
        <population>Patients who completed at least (3) treatment cycles.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 Alleles</title>
          <description>The number of patients with specific polymorphisms of UGT1A1 using genotype analysis of peripheral blood sample. UGT1A1*1 is the wild-type allele associated with normal enzyme activity. Patients with genotypic status of 7/7 are at an increased risk of neutropenia following intravenous irinotecan therapy.</description>
          <population>Patients who completed at least (3) treatment cycles.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>genotype 5/6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>genotype 6/6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>genotype 6/7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>genotype 7/7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Tumor DNA - Percentage of Patients With DNA Mutations</title>
        <description>Percentage of patients with Braf, Kras, Nras, PIK3CA and PTEN mutations associated with tumor detected in the circulating DNA of plasma, before treatment.</description>
        <time_frame>Baseline - prior to treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan + KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Tumor DNA - Percentage of Patients With DNA Mutations</title>
          <description>Percentage of patients with Braf, Kras, Nras, PIK3CA and PTEN mutations associated with tumor detected in the circulating DNA of plasma, before treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Braf mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kras mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nras mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Tumor DNA - Percentage of Patients With DNA Mutations</title>
        <description>Percentage of patients with Braf, Kras, Nras, PIK3CA and PTEN mutations associated with tumor detected in the circulating DNA of plasma, before treatment.</description>
        <time_frame>End of treatment - up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A - Irinotecan+ KD018</title>
            <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
          </group>
          <group group_id="O2">
            <title>Arm B - Irinotecan + Placebo</title>
            <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Tumor DNA - Percentage of Patients With DNA Mutations</title>
          <description>Percentage of patients with Braf, Kras, Nras, PIK3CA and PTEN mutations associated with tumor detected in the circulating DNA of plasma, before treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Braf mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kras mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nras mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A - Irinotecan + KD018</title>
          <description>KD018: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².</description>
        </group>
        <group group_id="E2">
          <title>Arm B - Irinotecan + Placebo</title>
          <description>Irinotecan: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Placebo: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="48" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="12" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="70" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" events="77" subjects_affected="10" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="34" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" events="39" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="27" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" events="23" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="20" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="20" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="62" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="22" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="72" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" events="26" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="28" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="14" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="16" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="12" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Chu, MD</name_or_title>
      <organization>UPMC Hillman Cancer Center</organization>
      <phone>(412) 648-6589</phone>
      <email>chue2@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

